Shrna Screening
Shrna Screening - Related Videos
09:12
MISSION LentiPlex Pooled shRNA Library Screening in Mammalian Cells
0 Views •
Cited by 11 •
2011
Here we use a human LentiPlex pooled library and traditional sequencing methods to identify gene targets promoting cell survival. We demonstrate how to set up and deconvolute a LentiPlex screen and validate the results.
11:15
Pooled shRNA Screen for Reactivation of MeCP2 on the Inactive X Chromosome
0 Views •
Cited by 2 •
2018
We report a small hairpin RNA (shRNA) and next generation sequencing-based protocol for identifying regulators of X-chromosome inactivation in a murine cell line with firefly luciferase and hygromycin resistance genes fused to the methyl CpG binding protein 2 (MeCP2) gene on the inactive X chromosome.
03:33
Generating Conditional Knockdown Cells Using a Tetracycline-Responsive Lentiviral shRNA Expression System
0 Views •
2026
Source: Kubala, M. H. & DeClerck, Y. A. Conditional Knockdown of Gene Expression in Cancer Cell Lines to Study the Recruitment of Monocytes/Macrophages to the Tumor Microenvironment. J. Vis. Exp. (2017)This video demonstrates the generation of conditional knockdown cancer cell lines using a Tet-inducible lentiviral shRNA system. It outlines the steps for viral transduction, antibiotic selection, and doxycycline-induced gene silencing.
14:51
Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype
0 Views •
Cited by 2 •
2022
High-throughput RNA interference (RNAi) screening using a pool of lentiviral shRNAs can be a tool to detect therapeutically relevant synthetic lethal targets in malignancies. We provide a pooled shRNA screening approach to investigate the epigenetic effectors in acute myeloid leukemia (AML).
03:47
Short Hairpin RNA-Mediated Gene Knockdown in iHSPCs In Vitro: A Lentivirus-Based shRNA Expression System Delivery into iHSPCs for Knockdown of Specific Gene Expression
0 Views •
2025
In this video, we demonstrate a method to perform transduction of shRNA lentiviral vectors to obtain stable knockdown cell lines in immortalized hematopoietic stem and progenitor cells (iHSPCs).
FAQs
After delivery, the short hairpin RNA is processed into a small interfering RNA molecule. This guide associates with the RNA-induced silencing complex, which recognizes complementary messenger RNA. The targeted messenger RNA can then be degraded or its translation repressed, reducing production of the corresponding protein and allowing researchers to examine downstream cellular or disease-related effects.
The same intended gene reduction may not occur equally across all shRNA sequences or experimental conditions. Variable knockdown efficiency can therefore influence the size of an observed phenotype, such as altered survival, proliferation, or signaling. Researchers use appropriate controls to distinguish a genuinely informative gene effect from a result caused by insufficient or inconsistent silencing.
Controls help determine whether a phenotype reflects silencing of the intended messenger RNA rather than unintended transcript effects. This issue is important because shRNA sequences are interpreted through their effects on cellular behavior, and off-target activity can mislead conclusions about disease mechanisms or therapeutic targets. Careful control design strengthens confidence when prioritizing genes for further study.
Changes in cell survival, proliferation, and signaling provide key readouts for linking reduced gene expression with biological function. In a disease-related model, these outcomes can indicate whether a gene supports or restrains a relevant cellular state. Such phenotype-to-gene relationships help researchers investigate mechanisms rather than relying only on the presence or abundance of a transcript.
A typical workflow uses a collection of shRNA sequences assembled as a library and delivered by vectors into the cells under study. Researchers then assess a selected cellular or disease-related phenotype and relate the observed change to the targeted gene. Controls are incorporated during interpretation to account for variable knockdown efficiency and off-target effects.
Medical researchers apply these screens to cancer cells, host-pathogen interactions, and drug-response pathways. The approach can reveal genes whose reduced expression changes survival, proliferation, or signaling in those settings. By connecting gene perturbation with a measurable phenotype, screening supports investigation of disease biology and helps identify candidates that merit additional therapeutic evaluation.
Genes that produce informative phenotype changes after knockdown can be examined as possible contributors to disease mechanisms or treatment responses. The results do not by themselves establish a therapy, but they help prioritize candidates for drug development. In medicine, this makes shRNA screening a tool for narrowing large gene sets toward targets with experimentally observed cellular relevance.